

Research Article

Effect of Chronic Valproic Acid Treatment on Hepatic Gene Expression Profile in *Wfs1* Knockout Mouse

Marite Punapart,^{1,2} Mall Eltermaa,^{1,2} Julia Oflijan,^{1,2} Silva Sütt,^{1,2} Anne Must,^{1,2}
Sulev Kõks,^{1,2} Leonard C. Schalkwyk,³ Catherine Fernandes,³ Eero Vasar,^{1,2}
Ursel Soomets,^{2,4} and Anton Terasmaa^{1,2}

¹ Institute of Biomedicine and Translational Medicine, Department of Physiology, University of Tartu, 19 Ravila Street, 50411 Tartu, Estonia

² Centre of Excellence for Translational Medicine, 19 Ravila Street, 50411 Tartu, Estonia

³ SGDP, Institute of Psychiatry at the Maudsley, King's College London, De Crespigny Park, London SE5 8AF, UK

⁴ Institute of Biomedicine and Translational Medicine, Department of Biochemistry, University of Tartu, 19 Ravila Street, 50411 Tartu, Estonia

Correspondence should be addressed to Anton Terasmaa; anton.terasmaa@ut.ee

Received 21 December 2013; Revised 17 February 2014; Accepted 17 February 2014; Published 1 April 2014

Academic Editor: Constantinos Giaginis

Copyright © 2014 Marite Punapart et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Valproic acid (VPA) is a widely used anticonvulsant and mood-stabilizing drug whose use is often associated with drug-induced weight gain. Treatment with VPA has been shown to upregulate *Wfs1* expression *in vitro*. Aim of the present study was to compare the effect of chronic VPA treatment in wild type (WT) and *Wfs1* knockout (KO) mice on hepatic gene expression profile. Wild type, *Wfs1* heterozygous, and homozygous mice were treated with VPA for three months (300 mg/kg i.p. daily) and gene expression profiles in liver were evaluated using Affymetrix Mouse GeneChip 1.0 ST array. We identified 42 genes affected by *Wfs1* genotype, 10 genes regulated by VPA treatment, and 9 genes whose regulation by VPA was dependent on genotype. Among the genes that were regulated differentially by VPA depending on genotype was peroxisome proliferator-activated receptor delta (*Ppard*), whose expression was upregulated in response to VPA treatment in WT, but not in *Wfs1* KO mice. Thus, regulation of *Ppard* by VPA is dependent on *Wfs1* genotype.

1. Introduction

Valproic acid (VPA) is a widely used mood stabilizer and anticonvulsant [1]. In addition to VPA's effect of alleviating mania in the treatment of bipolar disorder (BD) there are several secondary metabolic side effects associated with VPA treatment, namely, a higher risk of developing insulin resistance and weight gain [2]. Weight gain has been reported nearly in half of the patients using VPA as a treatment [3]. In the case of BD patients, drug-induced weight gain is particularly noteworthy since overweight and several other metabolic disturbances are more common among

people with BD compared to the general population [4]. The mechanism of VPA treatment-induced weight gain is unknown.

Impaired endoplasmic reticulum (ER) stress response was proposed to be associated with BD [5]. X box binding protein (XBPI) is a transcription factor of the ER stress response pathway. A mutation in this gene (-116C/G) is associated with bipolar disorder in the Japanese population [6] and XBPI expression is reduced in patients with BD [7, 8]. Wolframin (*WFS1*) is one of the genes that is induced in response to ER stress via XBPI [9]. It has been shown that mood stabilizers lithium and VPA facilitate the ER stress

response [10] and VPA induces *WFS1* expression *in vitro* [11]. VPA has also been shown to regulate the expression of other members of the ER stress pathway *in vitro* [12, 13] and *in vivo* [14].

Wfs1 is a 890 amino acid long transmembrane protein located in the ER. Lack of *WFS1* function results in impaired ER stress response and apoptosis [9, 15–17]. Homozygous mutations in the *WFS1* gene result in a rare disease—Wolfram syndrome that is characterized by early-onset *diabetes mellitus*, progressive optic atrophy, *diabetes insipidus*, and deafness [18, 19]. The frequency of heterozygous carriers of mutations in the *WFS1* gene is remarkably high—1% of the general population [20] and heterozygosity for the *WFS1* mutations has been reported to be a significant risk factor for psychiatric illnesses [20, 21]. Mutations in the *WFS1* gene have been reported in patients with bipolar disorder, major depression, schizophrenia, and suicide victims without Wolfram syndrome [18, 19, 22–31]. There are conflicting reports on the connection between the *WFS1* gene and bipolar disorder. Kato et al. found no association of *WFS1* polymorphisms and expression level in postmortem tissue of Japanese BD patients [32], and similar results were found in another study in Japanese patients [27]. Nevertheless, a recent meta-analysis of genome-wide expression studies on BD revealed *WFS1* to be significantly correlated with BD in the prefrontal cortex [33]. *Wfs1* KO mice were suggested as a possible animal model of BD [34]. We therefore hypothesize that the lack of *Wfs1* function in *Wfs1* KO mice mimics to a certain extent the aberrant ER stress response observed in some patients with BD.

Wfs1 KO mice exhibit impaired glucose tolerance and they are significantly smaller than their wild type littermates despite elevated growth hormone (GH) and insulin-like growth factor (IGF-1) levels [35]. In our previous study we found that acute treatment with valproic acid normalizes glucose tolerance in *Wfs1* mutant mice [36]. This effect of VPA was not mediated via increased insulin secretion, since the effect of VPA was also observed in mice with streptozotocin-induced type 1 diabetes. Thus, acute VPA treatment mimics and potentiates the effect of insulin in diabetic mice [36]. This study was conceived to investigate the effect of chronic administration of VPA on glucose tolerance and also on the gene expression in a metabolically relevant tissue. The liver was chosen as this organ plays an important role in the effect of insulin on the regulation of glucose metabolism, and also the expression level of *Wfs1* is substantial in the liver [37].

As male *Wfs1* KO mice exhibit stronger phenotype than female mice and *Wfs1* KO mice are smaller than wild type littermates the study was done on male young mice and a three-month long treatment was chosen to evaluate the possible effect of chronic VPA treatment on the growth of *Wfs1* mutant mice.

By comparing drug-induced changes of gene expression in wild type and *Wfs1* KO mice we hoped to find the genes that are potentially involved in the VPA treatment-induced metabolic alterations seen in BD patients.

2. Materials and Methods

2.1. Animals. Mice were housed under standard laboratory conditions on a 12 h light/dark cycle (lights on at 07:00 AM) with free access to regular chow diet (R70 Lantmännen, Sweden) and water. All animal experiments in this study were performed in accordance with the European Communities Directive (86/609/EEC) and a permit (number 39, October 7, 2005) from the Estonian National Board of Animal Experiments. Male wild type and *Wfs1* mutant mice were used throughout this study; they were 4 to 6 weeks old at the beginning of the experiment. Mice were treated for three months with valproic acid (VPA, Sigma Aldrich, 300 mg/kg i.p. daily) or vehicle (0.9% saline 10 mL/kg i.p. daily). Dose of VPA for chronic study was chosen as described previously [14]. A glucose tolerance test (2 g/kg i.p.) was performed 24 hours after the last VPA injection and mice were killed 24 hours after the glucose tolerance test. The liver was dissected out, snap frozen in liquid nitrogen, and stored at -80°C until further analysis. Mice were 16 to 18 weeks old when killed. Each experimental group consisted of 8 animals. Generation of *Wfs1* mutant mice was described previously [35].

2.2. Glucose Tolerance Test. Mice were kept in their home cages with free access to food and water. Food was removed 60 minutes prior to the experiment. Basal levels of blood glucose were determined from the tail vein; thereafter mice were injected with glucose (2 g/kg, i.p.) and blood glucose levels were determined using a hand held glucose meter (Accu-Check Go, Roche, Mannheim, Germany) at 30, 60, and 90 minutes following glucose injection.

2.3. Preparation of RNA and Microarray Hybridization. Total liver RNA was extracted using Trizol reagent (Ambion, Life Technologies). Integrity of total RNA was evaluated using the Agilent Bioanalyzer 2100 system (Agilent Technologies, CA, USA) and was within RNA integrity number (RIN) 7 to 9 and thus considered suitable for further processing. 300 nanograms of total RNA were processed to produce fragmented biotin-labeled cRNA using the Ambion WT expression kit according to manufacturer's instructions. Samples were hybridized Affymetrix GeneChip Mouse Gene 1.0 ST arrays and quantified. Images were processed and cell intensity files (CEL files) were generated in the GeneChip Command Console Software (Affymetrix). CEL files were processed using Expression Console v.1.1.2800.28061 to yield RMA summarized Log₂ transformed expression values for probesets (CHP files). Normalized expression data (CHP files) were analysed using ANOVA in R (genotype x treatment) using R package Bioconductor. The data discussed in this publication have been deposited in NCBI's Gene Expression Omnibus [38] and are accessible through GEO Series accession number GSE55143 (<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE55143>).

2.4. Microarray Data Analysis. Raw data from gene chips were processed with the RMA method, which involves quantile normalization. Two-way ANOVA was performed on

the normalized expression data using R software. A gene list was created that contained probesets with $P < 0.001$ for genotype effects. Only genes showing significantly different changes greater than 2-fold were considered for effect of genotype. For the effect of VPA treatment a P value of 0.001 was used as a cutoff. Given the small number of genes for which genotype-treatment interaction was established, a P value of 0.003 was used as a cutoff.

Differently expressed genes were annotated to find the molecular function using the web-based international database Mouse Genome Informatics Gene Ontology (MGI GO) that includes genetic, biological, and genomic information of laboratory mouse and also the UniProt Knowledgebase (UniProtKB/Swiss-Prot) that holds the functional information of known proteins.

2.5. Gene Expression Studies with qRT-PCR Analysis. For confirming differences in expression of genes of interest found on gene chip, quantitative real-time PCR (qRT-PCR) analysis was used. For that purpose, the ABI PRISM 7900HT Fast Real-Time PCR System equipment (PE Applied Biosystems, USA) and the ABI PRISM 7900 SDS 2.2.2 Software were used. In all gene expression experiments, cytoplasmic β -actin (*Actb*) (VIC/MGB Probe, Primer Limited) was used as the endogenous reference gene (PE Applied Biosystems, USA). All reactions were performed using the TaqMan Gene Expression Master Mix (PE Applied Biosystems, USA) and the TaqMan Gene Expression Assays (FAM) according to the instructions of the equipment and reagent manufacturers. All samples to be compared were run in the same experiment and every reaction was run in quadruplicate. The amount of the target gene was compared to the housekeeper gene by means of the $2^{-\Delta CT}$ method [39]. The following TaqMan Gene Expression Assays (FAM) were used: *Ppard* (Mm00803184_m1); *Fmo2* (Mm0049019_m1); *Sult3a1* (Mm00491057_m1); *Lepr* (Mm0040181_m1); *Wfs1* (Mm01220326_m1).

2.6. Statistics. Data are presented as means \pm SEM and were compared by two-way analysis of variance (ANOVA, treatment and genotype as the independent factors) followed by Tukey's post hoc test. A P value of <0.05 was considered statistically significant. Statistical analysis was performed using STATISTICA version 9 (StatSoft Ltd., Bedford, UK) and GraphPad Prism version 5 software (GraphPad Software Inc., San Diego, CA, USA).

3. Results

3.1. Description of *Wfs1* KO mice. To determine the effect of VPA treatment on growth, the weight of WT, *Wfs1* HZ, and *Wfs1* KO mice was recorded weekly for 14 weeks. At the age of 16 weeks, homozygous *Wfs1* KO mice had a remarkably lower mean body weight than wild type (WT) or heterozygous (HZ) mice ($F(2, 35) = 7.97$; $P = 0.0014$) (Figure 1). There were noticeably different growth rates between the genotypes starting from 8th to 9th week of age, when the growth of *Wfs1* KO was retarded, while the body weight of WT and HZ




FIGURE 1: Body weight of male WT and *Wfs1* mutant mice. At the age of 16 months, *Wfs1* KO (red circles) had lower body weight than WT (black circles) or heterozygous HZ (green circles) mice ($F(2, 35) = 7.97$; $P = 0.0014$). Growth rate of *Wfs1* KO mice was inhibited since 8th to 9th week of age, while the body weight of WT and HZ continued to increase ($F(24, 420) = 9.65$; $P < 0.000001$). Chronic administration of VPA for 3 months (300 mg/kg/day, i.p. solid symbols) had no effect on growth rate regardless of genotype ($F(1, 35) = 1.43$; $P = 0.2393$). Data is presented as mean \pm SEM ($n = 8$).

continued to increase ($F(24, 420) = 9.65$; $P < 0.000001$). Chronic administration of VPA for 3 months had no effect on growth regardless of genotype, confirmed by Tukey's HSD ($F(1, 35) = 1.43$; $P = 0.2393$).

3.2. Glucose Tolerance Test after Chronic VPA Treatment. Basal blood glucose levels of saline treated mice were slightly but significantly elevated in the KO group as compared to the WT or HZ group ($F(2, 21) = 10.03$; $P = 0.00088$). Administration of glucose (2 g/kg i.p.) induced a rise in blood glucose levels with a peak at 30 min following glucose administration in all genotypes (Figure 2(a)); this increase was the highest in *Wfs1* KO mice ($F(2, 21) = 75.71$; $P = 0.000001$). Tukey's HSD test confirmed peak blood glucose levels of the KO group being significantly higher compared to the WT or HZ group ($P = 0.00014$); also blood glucose levels in the homozygous group were higher than in WT ($P = 0.026$).

Chronic administration of VPA had no effect on the basal blood glucose levels regardless of genotype ($F(1, 43) = 0.52$; $P = 0.475$) but resulted in an increase of peak blood glucose concentration at 30 min in WT but not in *Wfs1* HZ or KO mice ($F(1, 43) = 17.31$; $P = 0.00015$). Tukey's HSD test confirmed peak blood glucose levels of VPA treated WT mice being significantly higher than in saline treated WT mice ($P = 0.0014$). VPA had no effect on peak blood glucose concentration in *Wfs1* KO or HZ mice. However, there was




FIGURE 2: Glucose tolerance test in male WT and *Wfs1* mutant mice after 3-month VPA treatment (300 mg/kg/day). (a) Time course of blood glucose levels following glucose challenge (2 g/kg, i.p.). Blood glucose was measured from tail vein immediately before and 30, 60, and 90 minutes following glucose administration. VPA treatment (solid circles) had no effect on glucose tolerance in *Wfs1* KO or *Wfs1* HZ mice when compared to respective vehicle group (0.9% saline, 10 mL/kg, i.p., open circles). (b) Area under the curve of glucose time curves. Two-way ANOVA followed by Tukey's HSD test (***) $P < 0.001$ versus (+/+SAL); \$\$\$ $P < 0.001$ versus (+/+VPA); \$ $P < 0.05$ versus (-/-SAL)). Data is presented as mean \pm SEM ($n = 8$).

no statistically significant effect of VPA treatment-genotype interaction ($F(2, 43) = 2.867$; $P = 0.0677$).

Wfs1 KO mice had largest area under the curve (AUC) of IPGTT test ($F(2, 43) = 52.81$; $P = 0.000001$), Tukey's HSD test confirmed *Wfs1* KO mice having greater AUC than WT ($P = 0.00014$) or HZ mice ($P = 0.00068$). There was no difference of AUC values between WT and *Wfs1* HZ group. Chronic administration of VPA resulted in an increase of AUC ($F(1, 43) = 14.16$; $P = 0.0005$); Tukey's HSD test confirmed VPA treated *Wfs1* KO mice having greater AUC than saline treated *Wfs1* KO mice ($P = 0.025$). Chronic treatment with VPA had no effect on AUC values in WT ($P = 0.099$) and *Wfs1* HZ mice ($P = 0.99$).

3.3. Hepatic Gene Transcription Profile. Total RNA was extracted from the liver of male mice and analysed using the Affymetrix GeneChip Mouse Gene 1.0 ST Array. Quality of microarray hybridization and distribution of raw signal

intensity across microarray chips was uniform across 48 samples (data not shown).

We did not see a decrease in expression of *Wfs1* gene in *Wfs1* KO mice using gene chip array. Affymetrix GeneChip Mouse Gene 1.0 ST Array has a probe for every exon of the gene. Our *Wfs1* mutant mouse was created by invalidating just two exons (7 and 8) of the *Wfs1* gene; the remaining six exons of this gene are intact in *Wfs1* KO mice. Thus, we did not detect decreased expression levels of *Wfs1* gene in *Wfs1* KO mice using these arrays. However, exon specific analysis revealed lower expression of exons 7 and 8 of *Wfs1* gene in *Wfs1* KO mice (data not shown).

We identified large number of genes that are differentially expressed depending on *Wfs1* genotype. There were 23 upregulated and 19 downregulated genes in *Wfs1* KO mice as compared to WT mice (Table 1). Ten genes were regulated by VPA treatment (Table 2) and further 9 genes showed an interaction between genotype and VPA treatment (Table 3).

TABLE 1: List of genes whose expression in mouse liver is regulated by *Wfs1* genotype as measured by Affymetrix GeneChip Mouse Gene 1.0 ST Array.

Probeset ID	<i>P</i> value	Q-value	Fold change	Gene	Gene description
Upregulated in <i>Wfs1</i> KO mice					
10362464	6.32E – 05	0.028767	131.3	Sult3a1	Sulfotransferase family 3A, member 1
10359593	4.94E – 06	0.008869	112.2	Fmo3	Flavin containing monooxygenase 3
10551209	3.81E – 04	0.055722	37.6	Cyp2b13	Cytochrome P450, family 2, subfamily b, polypeptide 13
10465726	8.82E – 06	0.011336	14.0	BC014805	cDNA sequence BC014805
10561162	7.93E – 05	0.031687	10.3	Cyp2a22	Cytochrome P450, family 2, subfamily a, polypeptide 22
10465734	3.50E – 06	0.008869	9.8	AB056442	cDNA sequence AB056442
10500570	1.07E – 04	0.035569	6.3	Hao2	Hydroxyacid oxidase 2
10506301	1.46E – 05	0.013481	5.2	Lepr	Leptin receptor
10425822	7.17E – 04	0.080582	5.0	Pnpla3	Patatin-like phospholipase domain containing 3
10520622	5.54E – 15	1.79E – 10	4.8	Abhd1	Abhydrolase domain containing 1
10468239	4.10E – 04	0.05785	4.4	Cyp17a1	Cytochrome P450, family 17, subfamily a, polypeptide 1
10359582	9.44E – 07	0.004726	4.4	Fmo2	Flavin containing monooxygenase 2
10397158	1.19E – 04	0.037527	3.5	Acot3	acyl-CoA thioesterase 3
10574027	7.39E – 04	0.081551	3.5	Mt1	Metallothionein 1
10533401	7.42E – 04	0.081551	2.9	Cux2	Cut-like homeobox 2
10350733	3.59E – 04	0.053424	2.8	Rgs16	Regulator of G-protein signaling 16
10465740	2.81E – 04	0.049115	2.4	Gm6192	Predicted gene 6192
10362472	2.97E – 04	0.050271	2.2	Rsph4a	Radial spoke head 4 homolog A (Chlamydomonas)
10467372	6.13E – 05	0.028301	2.1	Cyp2c38	Cytochrome P450, family 2, subfamily c, polypeptide 38
10519527	1.29E – 04	0.038113	2.1	Abcb1a	ATP-binding cassette, sub-family B (MDR/TAP), member 1A
10529977	3.97E – 06	0.008869	2.1	Ppargc1a	Peroxisome proliferative activated receptor, gamma, coactivator 1 alpha
10548996	4.56E – 04	0.062377	2.0	Slco1a4	Solute carrier organic anion transporter family, member 1a4
10515187	6.50E – 04	0.07526	2.0	Cyp4a14	Cytochrome P450, family 4, subfamily a, polypeptide 14
Downregulated in <i>Wfs1</i> KO mice					
10571560	1.68E – 04	0.03933	2.0	Mtnr1a	Melatonin receptor 1A
10597875	1.21E – 05	0.01261	2.0	Cyp8b1	Cytochrome P450, family 8, subfamily b, polypeptide 1
10454015	1.42E – 05	0.01348	2.0	Ttc39c	Tetratricopeptide repeat domain 39C
10502214	5.25E – 06	0.00892	2.2	Cyp2u1	Cytochrome P450, family 2, subfamily u, polypeptide 1
10498584	9.12E – 06	0.01133	2.4	Rarres1	Retinoic acid receptor responder (tazarotene induced) 1
10482528	2.47E – 05	0.01781	2.5	Neb	Nebulin
10579649	4.58E – 05	0.02463	2.6	Cib3	Calcium and integrin binding family member 3
10415279	2.82E – 05	0.01939	2.6	Fitm1	Fat storage-inducing transmembrane protein 1
10602372	2.33E – 06	0.00740	2.6	Alas2	Aminolevulinic acid synthase 2, erythroid
10548931	1.53E – 04	0.03829	2.7	Slc15a5	Solute carrier family 15, member 5
10500545	1.25E – 04	0.03811	2.8	Hsd3b5	Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 5
10507152	2.10E – 04	0.04265	3.0	Cyp4a12b	Cytochrome P450, family 4, subfamily a, polypeptide 12B
10352439	4.13E – 06	0.00886	3.1	Susd4	Sushi domain containing 4
10507143	1.99E – 04	0.04099	3.1	Cyp4a12a	Cytochrome P450, family 4, subfamily a, polypeptide 12a
10513538	9.25E – 05	0.03306	3.1	Mup21	Major urinary protein 21
10545877	4.37E – 07	0.00353	3.5	Nat8	N-Acetyltransferase 8 (GCN5-related, putative)
10497381	3.81E – 07	0.00353	3.9	Cyp7b1	Cytochrome P450, family 7, subfamily b, polypeptide 1
10545874	5.38E – 05	0.02674	4.6	Cml5	Camello-like 5
10463551	1.06E – 07	0.00171	6.4	Elov13	Elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like 3

TABLE 2: List of genes whose expression in mouse liver is regulated by chronic VPA treatment as measured by Affymetrix GeneChip Mouse Gene 1.0 ST Array.

Probeset ID	P value	Q-value	Fold change	Gene symbol	Gene description
10454353	1.81E - 04	0.66000	1.59	S100a10	S100 calcium binding protein A10 (calpactin)
10425421	2.87E - 04	0.738978	1.46	Pcna	Proliferating cell nuclear antigen
10493995	1.60E - 04	0.660001	1.46	Fam83f	Family with sequence similarity 83, member F
10518069	9.94E - 04	0.754625	1.46	Efh2	EF hand domain containing 2
10383545	3.52E - 04	0.754625	1.45	Pcna	Proliferating cell nuclear antigen
10487930	6.38E - 04	0.754625	1.36	Tbcl19	TBC1 domain family, member 19
10461391	4.38E - 05	0.569567	1.35	Gpr39 // Lypd1	G protein-coupled receptor 39 // Ly6/Plaur domain containing 1
10521927	5.10E - 05	0.569567	1.35	E130311K13Rik	RIKEN cDNA E130311K13 gene
10349401	4.74E - 04	0.754625	1.30	Mocos	Molybdenum cofactor sulfuryase
10498477	9.13E - 04	0.754625	1.26	Foxk2	Forkhead box K2

3.4. Confirmation of Selected Hits by qRT-PCR. The change in expression levels of selected genes (*Sult3a1*, *Fmo2*, *Lepr*, and *Ppard*) was verified with qRT-PCR technique (Figure 3). qRT-PCR data showed similar expression levels as Affymetrix gene chip analysis (Figure 3).

The expression level of *Ppard* was elevated by VPA treatment ($F(1, 42) = 52.5$; $P < 0.000001$), and the effect was dependent on genotype ($F(2, 42) = 8.66$; $P = 0.0007$) as revealed by Affymetrix GeneChip data (Figure 3(a)). The induction of *Ppard* expression by VPA was strongest in WT mice and lowest in *Wfs1* KO mice. Similar results were obtained also by qRT-PCR analysis for effect of VPA treatment ($F(1, 42) = 36.34$; $P < 0.0000001$) and treatment-genotype interaction ($F(2, 42) = 10.8$; $P = 0.0002$, Figure 3(b)).

Expression of *Lepr* was highly elevated in liver of *Wfs1* KO mice in comparison to WT or *Wfs1* HZ mice ($F(2, 42) = 38.8$; $P < 0.000001$) as revealed by Affymetrix GeneChip data (Figure 3(c)). The effect of genotype on *Lepr* expression pattern was confirmed with qRT-PCR method ($F(2, 38) = 12.95$; $P = 0.00005$, Figure 3(d)). Two-way ANOVA revealed also inhibitory effect of VPA on the expression of *Lepr* according to Affymetrix GeneChip data ($F(1, 42) = 8.5$; $P = 0.0057$); however, such effect of VPA treatment was not confirmed by qRT-PCR analysis, possibly due to a large variation in *Wfs1* KO VPA group in qRT-PCR analysis (Figure 3(d)).

Expression level of *Sult3a1* in liver of male *Wfs1* KO mice was much higher than in male *Wfs1* HZ or male WT mice ($F(2, 42) = 22.5$; $P < 0.00001$) as revealed by Affymetrix gene chip, such finding was confirmed by qRT-PCR analysis ($F(2, 37) = 6.34$; $P = 0.004$). In fact, the expression level of *Sult3a1* in WT mice was below detection limit by qRT-PCR method. VPA treatment had no effect on expression level of *Sult3a1* (Figures 3(e) and 3(f)).

The expression level of *Fmo2* was dependent on genotype and VPA treatment as revealed by Affymetrix gene chip analysis (Figure 3(g)); its expression was higher in *Wfs1* KO as compared to WT mice ($F(2, 42) = 30.4$; $P < 0.000001$). The expression of *Fmo2* was inhibited by VPA treatment in all

genotypes ($F(1, 42) = 16.5$; $P = 0.0002$). Similar results were obtained also by qRT-PCR analysis for genotype ($F(2, 42) = 10.9$; $P = 0.001$) and VPA treatment ($F(1, 42) = 5.04$; $P = 0.03$, Figure 3(h)).

3.5. Regulation of *Wfs1* Expression by VPA. qRT-PCR analysis revealed that the expression level of *Wfs1* was elevated by VPA treatment ($F(1, 41) = 7.72$; $P = 0.0082$); however, there was no interaction of treatment with *Wfs1* genotype (Figure 4(a)). As expected, the expression level of *Wfs1* was dependent on genotype ($F(2, 41) = 15.38$; $P < 0.0001$); expression level of *Wfs1* in heterozygous mutant mice was reduced to 54% in comparison with wild type mice (Figure 4(a)). The expression level of *Wfs1* was compared to expression level of *Ppard* for possible interaction (expression of both genes was measured by qRT-PCR); regression coefficient of linear regression across all samples was $R^2 = 0.433$ ($P < 0.0001$, Figure 4(b)).

4. Discussion

The growth of *Wfs1* KO mice was retarded compared to WT or *Wfs1* HZ animals, confirming the results of our previous study [35]. Chronic treatment with VPA had no effect on the growth rate (Figure 1). Interestingly, the growth of *Wfs1* KO mice seems to be similar to that of WT mice until 8 weeks of age, but thereafter the growth of *Wfs1* KO mice slows down, while WT and *Wfs1* HZ mice continue to grow. The mechanism of such age dependency is not known but could be related to the sexual development of mice. We have shown that acute administration of VPA improves glucose tolerance of *Wfs1* KO and HZ mice [36], thus we wanted to evaluate the effect of chronic VPA administration in these mice. Interestingly, chronic treatment with VPA had no effect on basal blood glucose levels regardless of genotype (Figure 2). However, chronic VPA treatment resulted in increased peak glucose level during glucose tolerance test in WT mice and VPA treated *Wfs1* KO mice showed an increased area under the curve during glucose tolerance test. Therefore, chronic




FIGURE 3: Comparison of results from Affymetrix GeneChip Mouse Gene 1.0 ST Array and qRT-PCR analysis. qRT-PCR mRNA expression is represented as the mean of quadruplicate per sample against the endogenous reference gene *ACTB*. (a) and (b) *Ppard*. Upregulation of *Ppard* by valproic acid (VPA) is abolished by *Wfs1* invalidation. (c) and (d) *Lepr*. *Lepr* is upregulated in *Wfs1* KO mice. (e) and (f) *Sult3a1*. *Sult3a1* expression is increased in *Wfs1* KO mice while downregulated by VPA. (g) and (h) *Fmo2*. *Fmo2* expression level is increased in *Wfs1* KO mice. All data are presented as means \pm SEM ($n = 8$) and were compared by two-way analysis of variance (ANOVA) followed by Tukey's post hoc test (** $P < 0.01$, *** $P < 0.001$).

TABLE 3: List of genes whose expression in mouse liver by chronic VPA treatment is dependent on *Wfs1* genotype as measured by Affymetrix GeneChip Mouse Gene 1.0 ST Array.

Probeset ID	P value	Q-value	Fold changes	Gene symbol	Gene description
10443332	$1.1E - 04$	0.99999	2.26	<i>Ppard</i>	Peroxisome proliferator activator receptor delta
10409278	$2.1E - 03$	0.99999	2.17	<i>Nfil3</i>	Nuclear factor, interleukin 3, regulated
10417734	$5.6E - 04$	0.99999	2.03	<i>Nr1d2</i>	Nuclear receptor subfamily 1, group D, member 2
10514520	$1.9E - 03$	0.99999	1.58	<i>Cyp2j9</i>	Cytochrome P450, family 2, subfamily j, polypeptide 9
10535759	$9.2E - 04$	0.99999	1.32	<i>Lnx2</i>	Ligand of numb-protein X 2
10489694	$1.9E - 03$	0.99999	1.26	<i>Zfp334</i>	Zinc finger protein 334
10459353	$1.3E - 03$	0.99999	1.25	<i>Fam38b</i>	Family with sequence similarity 38, member B
10351414	$1.7E - 03$	0.99999	1.20	<i>Aldh9a1</i>	Aldehyde dehydrogenase 9, subfamily A1
10473690	$2.1E - 03$	0.99999	1.18	<i>Fnbp4</i>	Formin binding protein 4




FIGURE 4: qRT-PCR analysis of *Wfs1* expression in hepatic tissue of WT and *Wfs1* mutant mice. qRT-PCR mRNA expression is represented as the mean of quadruplicate per sample against the endogenous reference gene *Actb*. (a) Chronic treatment with valproic acid (VPA) induces upregulation of *Wfs1* expression ($F(1, 41) = 7.72$; $P = 0.0082$). Expression level of *Wfs1* follows a gene-dose relationship with *Wfs1* genotype ($F(2, 41) = 15.38$; $P < 0.0001$). All data are presented as means \pm SEM ($n = 8$) and were compared by two-way analysis of variance (ANOVA). (b) Relationship between the expression levels of *Wfs1* and *Ppard*, linear regression across all data points $R^2 = 0.433$ ($P < 0.0001$), and expression levels of *Ppard* and *Wfs1* were measured using qRT-PCR, each point corresponds to one animal.

VPA seems to impair glucose tolerance of *Wfs1* KO mice, contrary to its acute effect.

We identified a number of genes that are differentially expressed depending on *Wfs1* genotype; a few of them are regulated by VPA treatment. Animals were sacrificed 48 hours after last administration of valproic acid and it is possible that drug treatment effects are normalized during that time. Therefore, the genes showing persistent alteration might be the most relevant ones. We identified 23 upregulated and 19 downregulated genes in *Wfs1* KO mice as compared to WT mice (Table 1). Ten genes were altered by VPA treatment (Table 2) and further 9 genes showed an interaction with genotype and treatment (Table 3). The expression levels of four genes were evaluated by qRT-PCR, and the two methods gave qualitatively similar results.

Many of the genes which were dependent on the *Wfs1* genotype were functionally involved in oxidative processes, including cytochromes, proteins that participate in electron

transport (*Cyp2b13*, *Cyp2a22*, *Cyp17a1*, *Cyp2c38*, *Cyp4a14*, *Cyp8b1*, *Cyp2u1*, *Cyp4a12b*, and *Cyp7b1*), but also genes for monooxygenases (*Fmo3* and *Fmo2*) and organic anion transporters (BC014805, AB056442, *Abcb1a*, and *Slco1a4*). Some of the genes that were upregulated in *Wfs1* KO mice are involved in lipid metabolism (*Hao2*, *Lepr*, *Pnpla3*, *Acot3*, and *Ppargc1a*). Also, some of the genes with decreased expression in *Wfs1* KO mice are involved in fatty acid metabolism (*Rarres1*, *Fitm1*, *Hsd3b5*, and *Elovl3*). Interestingly, earlier reports found *Elovl3* to be upregulated in the liver in response to subchronic [40] and single administration of VPA [41].

The main aim of this study was to identify genes for which the regulation by chronic VPA treatment is dependent on the *Wfs1* genotype. The three genes with the largest change in expression were peroxisome proliferator activator receptor delta (*Ppard*), interleukin-3 regulated nuclear factor (*Nfil3*),

and nuclear receptor subfamily 1, group D, member 2 (*Nr1d2*); all of them are also linked with circadian rhythms [42].

In WT mice, VPA treatment caused an approximately 2-fold increase in the expression of *Ppard* compared to vehicle treatment. Such VPA induced upregulation of *Ppard* was not detected in the liver of *Wfs1* KO mice. These results were verified by qRT-PCR analysis (Figures 3(a) and 3(b)). Moreover, similar effect of VPA on *Ppard* expression was observed earlier using *in vitro* bioassays in CHO and F9 cell lines, where VPA activates *Ppard* gene expression [43, 44]. Thus, this finding is in agreement with earlier studies. Based on PPAR reporter assays, VPA is classified as a “triple ppar-alpha, -beta/delta, -gamma agonist” [45]. *Ppard* regulates the expression of its target gene *Pdk1* [46]; it is noteworthy that the expression of this kinase was found to be upregulated in response to VPA treatment in the liver slices [45].

PPARs are lipid-activated nuclear receptors with several physiological functions, including control of fatty acid metabolism in different tissues [47]. There are three different subtypes of PPAR: PPAR α , PPAR β/δ (*PPARD*), and PPAR γ , each having different expression and biological activities [48]. PPAR α is mainly expressed in tissues with intensive β -oxidation such as liver, kidneys, heart, skeletal muscles, and intestine. It has been apparent from the experimental and clinical trials that PPAR α is important for fatty acid oxidation in the liver and heart [48]. PPAR γ participates in the proliferation and differentiation of adipocytes. It is mainly expressed in the fat tissue, colon, endothelial cells, and in the smooth muscle cells of blood vessels [48–50]. *PPARD* is widely expressed, but its physiological roles are not as well understood as the ones of the other subtypes. *PPARD* participates in the skin healing process and is also important in controlling fatty acids oxidation in several tissues, for example, muscle and fat tissue [47, 51]. Recently, an intriguing role of *PPARD* in the regulation of hepatic lipogenic pathway and fat use by muscle was identified. Liver-specific *PPARD* activation increases fatty acid uptake in the muscle via regulation of circulating fatty acids [52]. In addition, *PPARD* activation intensifies glycolysis and the work of pentose phosphate shunt and promotes fatty acid synthesis [48, 53].

Activation of *PPARD* has beneficial effect on body weight and is proposed as treatment of type 2 diabetes [53]. Interestingly, mutations in the *PPARD* gene are associated with BD in the American population [54]; thus there might be also a direct deficit of *PPARD* in patients with BD leading to the development of metabolic syndrome. Activation of *PPARD* in respective patients needs to be measured to test such a hypothesis.

PPAR agonists are suggested as potential drugs in the case of overweight and problems associated with that [48, 55]. Moreover, *Ppard* interaction with hepatic AMPK (phospho-AMP-activated protein kinase), PGC-1 α (PPAR α -PPAR γ coactivator), and lipin-1 refers to them as therapeutic targets in the prevention of dyslipidemia [51]. It was recently shown that *Ppard* agonist GW501516 prevents high fat diet associated hyperglyceridemia [56]. GW501516 also restores hepatic AMPK level, which is decreased with the overconsumption of fat, and enhances lipin-1-PGC-1 α dependent

pathway rising hepatic fatty acids oxidation [56]. Remarkably, *Ppar γ 1c1a* is one of the genes whose expression was significantly higher in *Wfs1* KO mice compared to WT mice (Table 1).

It is unknown whether *Wfs1* is required for VPA mediated induction of *Ppard* expression or lack of VPA effect in *Wfs1* KO mice is caused by some secondary changes in these mice. Chronic VPA treatment results in an increase of *Wfs1* expression (Figure 4(a)). There seems to be a correlation between the expression levels of *Wfs1* and *Ppard* (Figure 4(b)), further suggesting a regulatory link between these two genes. However, molecular studies linking *Wfs1* function with the regulation of *Ppard* are needed to definitely answer this question. Also, it would be most interesting to compare the regulation of PPAR in patients with and without VPA treatment-induced weight gain. Based on our results, we would speculate that PPAR is activated in patients without drug induced weight gain, while its activity is lower in obese patients receiving VPA.

It is hard to predict whether PPAR ligands will eventually be developed into FDA-approved drugs. Results of this study suggest that these drugs must be evaluated for possible interaction with valproic acid before use in patients.

5. Conclusions

GeneChip analysis showed that invalidation of the *Wfs1* gene induces changes in liver transcriptome with impact on genes involved in lipid and fatty acid metabolism. Expression of *Ppard* in the liver is upregulated in response to chronic treatment with valproic acid, such upregulation is absent in *Wfs1* KO mice. Importance of *Ppard* in the regulation of metabolic processes is well recognized; thus the role of such *Wfs1*-VPA interaction on the regulation of *Ppard* needs further investigation.

Conflict of Interests

The authors declare that there is no conflict of interests.

Acknowledgments

This study was supported by Grants GARFS 8414, GARBK 7856, and SF0180148s08 (TARFS0416) from Estonian Science Foundation, by exchange Grant 2949 from European Science Foundation, by the Centre of Translational Genomics of the University of Tartu (SPIGVARENG) and by a COST action BM901.

References

- [1] R. S. Jope and G. V. W. Johnson, “The glamour and gloom of glycogen synthase kinase-3,” *Trends in Biochemical Sciences*, vol. 29, no. 2, pp. 95–102, 2004.
- [2] S. Chateauvieux, F. Morceau, M. Dicato, and M. Diederich, “Molecular and therapeutic potential and toxicity of valproic acid,” *Journal of Biomedicine and Biotechnology*, vol. 2010, Article ID 479364, 18 pages, 2010.

- [3] A. Verrotti, C. D'Egidio, A. Mohn, G. Coppola, and F. Chiarelli, "Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications," *Obesity Reviews*, vol. 12, no. 501, pp. e32–e43, 2011.
- [4] H. H. Chang, C. H. Chou, P. S. Chen et al., "High prevalence of metabolic disturbances in patients with bipolar disorder in Taiwan," *Journal of Affective Disorders*, vol. 117, no. 1-2, pp. 124–129, 2009.
- [5] T. Kato, "Molecular neurobiology of bipolar disorder: a disease of "mood-stabilizing neurons"?" *Trends in Neurosciences*, vol. 31, no. 10, pp. 495–503, 2008.
- [6] C. Kakiuchi, M. Ishiwata, T. Umekage et al., "Association of the XBPI-116C/G polymorphism with schizophrenia in the Japanese population," *Psychiatry and Clinical Neurosciences*, vol. 58, no. 4, pp. 438–440, 2004.
- [7] C. Kakiuchi, K. Iwamoto, M. Ishiwata et al., "Impaired feedback regulation of XBPI as a genetic risk factor for bipolar disorder," *Nature Genetics*, vol. 35, no. 2, pp. 171–175, 2003.
- [8] J. So, J. J. Warsh, and P. P. Li, "Impaired endoplasmic reticulum stress response in B-lymphoblasts from patients with bipolar-I disorder," *Biological Psychiatry*, vol. 62, no. 2, pp. 141–147, 2007.
- [9] C. Kakiuchi, M. Ishiwata, A. Hayashi, and T. Kato, "XBPI induces *WFSI* through an endoplasmic reticulum stress response element-like motif in SH-SY5Y cells," *Journal of Neurochemistry*, vol. 97, no. 2, pp. 545–555, 2006.
- [10] D.-M. Chuang, "The antiapoptotic actions of mood stabilizers: molecular mechanisms and therapeutic potentials," *Annals of the New York Academy of Sciences*, vol. 1053, pp. 195–204, 2005.
- [11] C. Kakiuchi, S. Ishigaki, C. M. Osowski, S. G. Fonseca, T. Kato, and F. Urano, "Valproate, a mood stabilizer, induces *WFSI* expression and modulates its interaction with ER stress protein GRP94," *PLoS ONE*, vol. 4, no. 1, Article ID e4134, 2009.
- [12] C. D. Bown, J.-F. Wang, and L. T. Young, "Increased expression of endoplasmic reticulum stress proteins following chronic valproate treatment of rat C6 glioma cells," *Neuropharmacology*, vol. 39, no. 11, pp. 2162–2169, 2000.
- [13] L. Shao, X. Sun, L. Xu, L. T. Young, and J.-F. Wang, "Mood stabilizing drug lithium increases expression of endoplasmic reticulum stress proteins in primary cultured rat cerebral cortical cells," *Life Sciences*, vol. 78, no. 12, pp. 1317–1323, 2006.
- [14] B. Chen, J. F. Wang, and L. T. Young, "Chronic valproate treatment increases expression of endoplasmic reticulum stress proteins in the rat cerebral cortex and hippocampus," *Biological Psychiatry*, vol. 48, no. 7, pp. 658–664, 2000.
- [15] T. Yamada, H. Ishihara, A. Tamura et al., "*WFSI*-deficiency increases endoplasmic reticulum stress, impairs cell cycle progression and triggers the apoptotic pathway specifically in pancreatic β -cells," *Human Molecular Genetics*, vol. 15, no. 10, pp. 1600–1609, 2006.
- [16] K. Ueda, J. Kawano, K. Takeda et al., "Endoplasmic reticulum stress induces *Wfs1* gene expression in pancreatic β -cells via transcriptional activation," *European Journal of Endocrinology*, vol. 153, no. 1, pp. 167–176, 2005.
- [17] S. G. Fonseca, M. Fukuma, K. L. Lipson et al., "*WFSI* is a novel component of the unfolded protein response and maintains homeostasis of the endoplasmic reticulum in pancreatic β -cells," *The Journal of Biological Chemistry*, vol. 280, no. 47, pp. 39609–39615, 2005.
- [18] T. M. Strom, K. Hörtnagel, S. Hofmann et al., "Diabetes insipidus, diabetes mellitus, optic atrophy and deafness (DID-MOAD) caused by mutations in a novel gene (Wolframin) coding for a predicted transmembrane protein," *Human Molecular Genetics*, vol. 7, no. 13, pp. 2021–2028, 1998.
- [19] H. Inoue, Y. Tanizawa, J. Wasson et al., "A gene encoding a transmembrane protein is mutated in patients with diabetes mellitus and optic atrophy (Wolfram syndrome)," *Nature Genetics*, vol. 20, no. 2, pp. 143–148, 1998.
- [20] R. G. Swift, D. O. Perkins, C. L. Chase, D. B. Sadler, and M. Swift, "Psychiatric disorders in 36 families with Wolfram syndrome," *The American Journal of Psychiatry*, vol. 148, no. 6, pp. 775–779, 1991.
- [21] M. Swift and R. G. Swift, "Psychiatric disorders and mutations at the Wolfram syndrome locus," *Biological Psychiatry*, vol. 47, no. 9, pp. 787–793, 2000.
- [22] T. D. Als, H. A. Dahl, T. J. Flint et al., "Possible evidence for a common risk locus for bipolar affective disorder and schizophrenia on chromosome 4p16 in patients from the Faroe Islands," *Molecular Psychiatry*, vol. 9, no. 1, pp. 93–98, 2004.
- [23] R. Cheng, S. H. Juo, J. E. Loth et al., "Genome-wide linkage scan in a large bipolar disorder sample from the National Institute of Mental Health genetics initiative suggests putative loci for bipolar disorder, psychosis, suicide, and panic disorder," *Molecular Psychiatry*, vol. 11, no. 3, pp. 252–260, 2006.
- [24] H. Ewald, B. Degen, O. Mors, and T. A. Kruse, "Support for the possible locus on chromosome 4p16 for bipolar affective disorder," *Molecular Psychiatry*, vol. 3, no. 5, pp. 442–448, 1998.
- [25] H. Ewald, T. Flint, T. A. Kruse, and O. Mors, "A genome-wide scan shows significant linkage between bipolar disorder and chromosome 12q24.3 and suggestive linkage to chromosomes 1p22–21, 4p16, 6q14–22, 10q26 and 16p13.3," *Molecular Psychiatry*, vol. 7, no. 7, pp. 734–744, 2002.
- [26] S. D. Detera-Wadleigh, C.-Y. Liu, M. Maheshwari et al., "Sequence variation in *DOCK9* and heterogeneity in bipolar disorder," *Psychiatric Genetics*, vol. 17, no. 5, pp. 274–286, 2007.
- [27] T. Ohtsuki, H. Ishiguro, T. Yoshikawa, and T. Arinami, "*WFSI* gene mutation search in depressive patients: detection of five missense polymorphisms but no association with depression or bipolar affective disorder," *Journal of Affective Disorders*, vol. 58, no. 1, pp. 11–17, 2000.
- [28] L. Martorell, M. Gómez Zaera, J. Valero et al., "The *WFSI* (Wolfram syndrome 1) is not a major susceptibility gene for the development of psychiatric disorders," *Psychiatric Genetics*, vol. 13, no. 1, pp. 29–32, 2003.
- [29] R. Torres, E. Leroy, X. Hu et al., "Mutation screening of the Wolfram syndrome gene in psychiatric patients," *Molecular Psychiatry*, vol. 6, no. 1, pp. 39–43, 2001.
- [30] J. Crawford, M. A. Zielinski, L. J. Fisher, G. R. Sutherland, and R. D. Goldney, "Is there a relationship between Wolfram syndrome carrier status and suicide?" *American Journal of Medical Genetics—Neuropsychiatric Genetics*, vol. 114, no. 3, pp. 343–346, 2002.
- [31] K. L. Evans, D. Lawson, T. Meitinger, D. H. Blackwood, and D. J. Porteous, "Mutational analysis of the Wolfram syndrome gene in two families with chromosome 4p-linked bipolar affective disorder," *American Journal of Medical Genetics*, vol. 96, no. 2, pp. 158–160, 2000.
- [32] T. Kato, K. Iwamoto, S. Washizuka et al., "No association of mutations and mRNA expression of *WFSI*/wolframin with bipolar disorder in humans," *Neuroscience Letters*, vol. 338, no. 1, pp. 21–24, 2003.

- [33] F. Seifuddin, M. Pirooznia, J. T. Judy et al., "Systematic review of genome-wide gene expression studies of bipolar disorder," *BMC Psychiatry*, vol. 13, article 213, 2013.
- [34] T. Kato, M. Ishiwata, K. Yamada et al., "Behavioral and gene expression analyses of *Wfs1* knockout mice as a possible animal model of mood disorder," *Neuroscience Research*, vol. 61, no. 2, pp. 143–158, 2008.
- [35] S. Kōks, U. Soomets, J. L. Paya-Cano et al., "*Wfs1* gene deletion causes growth retardation in mice and interferes with the growth hormone pathway," *Physiological Genomics*, vol. 37, no. 3, pp. 249–259, 2009.
- [36] A. Terasmaa, U. Soomets, J. Oflijan et al., "*Wfs1* mutation makes mice sensitive to insulin-like effect of acute valproic acid and resistant to streptozocin," *Journal of Physiology and Biochemistry*, vol. 67, no. 3, pp. 381–390, 2011.
- [37] M. de Falco, L. Manente, A. Lucariello et al., "Localization and distribution of Wolfram in human tissues," *Frontiers in Bioscience*, vol. 4, pp. 1986–1998, 2012.
- [38] R. Edgar, M. Domrachev, and A. E. Lash, "Gene Expression Omnibus: NCBI gene expression and hybridization array data repository," *Nucleic Acids Research*, vol. 30, no. 1, pp. 207–210, 2002.
- [39] K. J. Livak and T. D. Schmittgen, "Analysis of relative gene expression data using real-time quantitative PCR and the $2^{-\Delta\Delta C_T}$ method," *Methods*, vol. 25, no. 4, pp. 402–408, 2001.
- [40] M.-H. Lee, M. Kim, B.-H. Lee et al., "Subchronic effects of valproic acid on gene expression profiles for lipid metabolism in mouse liver," *Toxicology and Applied Pharmacology*, vol. 226, no. 3, pp. 271–284, 2008.
- [41] M.-H. Lee, I. Hong, M. Kim et al., "Gene expression profiles of murine fatty liver induced by the administration of valproic acid," *Toxicology and Applied Pharmacology*, vol. 220, no. 1, pp. 45–59, 2007.
- [42] J. Yan, H. Wang, Y. Liu, and C. Shao, "Analysis of gene regulatory networks in the mammalian circadian rhythm," *PLoS Computational Biology*, vol. 4, no. 10, Article ID e1000193, 2008.
- [43] M. Göttlicher, S. Heck, and P. Herrlich, "Transcriptional cross-talk, the second mode of steroid hormone receptor action," *Journal of Molecular Medicine*, vol. 76, no. 7, pp. 480–489, 1998.
- [44] A. Lampen, S. Siehler, U. Ellerbeck, M. Göttlicher, and H. Nau, "New molecular bioassays for the estimation of the teratogenic potency of valproic acid derivatives *in vitro*: activation of the peroxisomal proliferator-activated receptor (PPAR δ)," *Toxicology and Applied Pharmacology*, vol. 160, no. 3, pp. 238–249, 1999.
- [45] E. Szalowska, B. van der Burg, H. Y. Man, P. J. Hendriksen, and A. A. Peijnenburg, "Model steatogenic compounds (amiodarone, valproic Acid, and tetracycline) alter lipid metabolism by different mechanisms in mouse liver slices," *PLoS ONE*, vol. 9, no. 1, Article ID e86795, 2014.
- [46] N. di-Po, N. S. Tan, L. Michalik, W. Wahli, and B. Desvergne, "Antiapoptotic role of PPAR β in keratinocytes via transcriptional control of the Akt1 signaling pathway," *Molecular Cell*, vol. 10, no. 4, pp. 721–733, 2002.
- [47] P. A. Grimaldi, "Regulatory role of peroxisome proliferator-activated receptor delta (PPAR δ) in muscle metabolism. A new target for metabolic syndrome treatment?" *Biochimie*, vol. 87, no. 1, pp. 5–8, 2005.
- [48] S. Takahashi, T. Tanaka, and J. Sakai, "New therapeutic target for metabolic syndrome: PPAR δ ," *Endocrine Journal*, vol. 54, no. 3, pp. 347–357, 2007.
- [49] M. Adiels, S.-O. Olofsson, M.-R. Taskinen, and J. Borén, "Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome," *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 28, no. 7, pp. 1225–1236, 2008.
- [50] P. Balakumar, M. Rose, S. S. Ganti, P. Krishan, and M. Singh, "PPAR dual agonists: are they opening Pandora's Box?" *Pharmacological Research*, vol. 56, no. 2, pp. 91–98, 2007.
- [51] J. Lee and W. Y. Chung, "The role played by the peroxisome proliferator-activated receptor- β/δ (PPAR β/δ) activator, GW501516, in control of fatty acid metabolism: a new potential therapeutic target for treating metabolic syndrome," *Endocrinology*, vol. 152, no. 5, pp. 1742–1744, 2011.
- [52] S. Liu, J. D. Brown, K. J. Stanya et al., "A diurnal serum lipid integrates hepatic lipogenesis and peripheral fatty acid use," *Nature*, vol. 502, no. 7472, pp. 550–554, 2013.
- [53] C. H. Lee, P. Olson, A. Hevener et al., "PPAR δ regulates glucose metabolism and insulin sensitivity," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 103, no. 9, pp. 3444–3449, 2006.
- [54] P. P. Zandi, P. L. Belmonte, V. L. Willour et al., "Association study of Wnt signaling pathway genes in bipolar disorder," *Archives of General Psychiatry*, vol. 65, no. 7, pp. 785–793, 2008.
- [55] G. D. Barish, V. A. Narkar, and R. M. Evans, "PPAR δ : a dagger in the heart of the metabolic syndrome," *The Journal of Clinical Investigation*, vol. 116, no. 3, pp. 590–597, 2006.
- [56] E. Barroso, R. Rodríguez-Calvo, L. Serrano-Marco et al., "The PPAR β/δ activator GW501516 prevents the down-regulation of AMPK caused by a high-fat diet in liver and amplifies the PGC-1 α -lipin 1-PPAR α pathway leading to increased fatty acid oxidation," *Endocrinology*, vol. 152, no. 5, pp. 1848–1859, 2011.